证券代码：603309 证券简称：维力医疗 公告编号：2025-065 广州维力医疗器械股份有限公司 关于召开2025年第二次临时股东会的通知 2025年第二次临时股东会 (二)股东会召集人：董事会 (三)投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合的方 式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 12 月 11 日 14 点 30 分 召开地点：广州市番禺区化龙镇国贸大道南 47 号公司一号楼二楼会议室 (五)网络投票的系统、起止日期和投票时间。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一)股东会类型和届次 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 12 月 11 日 至2025 年 12 月 11 日 股东会召开日期：2025年12月11日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交 ...

一、董事会会议召开情况 广州维力医疗器械股份有限公司（以下简称"公司"）第五届董事会第十八 次会议的会议通知和材料于2025年11月21日以电子邮件方式发出，会议于2025 年11月25日上午10点在公司会议室以现场和通讯相结合的方式召开，会议由董事 长向彬先生主持，会议应出席董事7名，亲自出席董事7名。其中，董事段嵩枫先 生、独立董事芦春斌先生、独立董事欧阳文晋先生、独立董事臧传宝先生因出差 在外，以通讯表决方式参与本次会议。公司全体高级管理人员列席了会议。本次 会议的召集和召开程序符合《公司法》等有关法律、行政法规、部门规章、规范 性文件和《公司章程》的相关规定，会议形成的决议合法、有效。 证券代码：603309 证券简称：维力医疗 公告编号：2025-063 广州维力医疗器械股份有限公司 第五届董事会第十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司拟定于2025年12月11日下午14:30在公司一号楼二楼会议室召开公司 2025年第二次临时股东会。（具体内容详见同日刊登在《中国证券报》《上海证 ...

证券代码：603309 证券简称：维力医疗 公告编号：2025-064 重要内容提示： 一、利润分配预案内容 截至 2025 年 9 月 30 日，公司母公司报表中期末未分配利润为人民币 703,792,551.73 元（未经审计）。经董事会决议，公司 2025 年前三季度拟以实施 权益分派股权登记日登记的总股本为基数分配利润。本次利润分配预案如下： 公司拟向全体股东每 10 股派发现金红利 2 元（含税）。截至 2025 年 11 月 25 日，公司总股本 291,871,418 股，以此计算合计拟派发现金红利 58,374,283.60 元 （含税）。公司拟进行现金分红金额占 2025 年前三季度合并报表归属于上市公司股 东净利润比例为 30.46%。本次利润分配不送红股，不以公积金转增股本,剩余未分 配利润进行结转。 如在本公告披露之日起至实施权益分派股权登记日期间，公司总股本发生变动 的，公司拟维持每股分配比例不变，相应调整分配总额。如后续总股本发生变化， 将另行公告具体调整情况。 本次利润分配预案尚需提交公司股东会审议。 每股分配比例：每股派发现金红利 0.2 元（含税） 本次利润分配以实施权益分派 ...

人民财讯11月25日电，维力医疗(603309)11月25日公告，截至2025年9月30日，公司母公司报表中期末 未分配利润为7.04亿元（未经审计）。经董事会决议，公司2025年前三季度拟以实施权益分派股权登记 日登记的总股本为基数分配利润。公司拟向全体股东每10股派发现金红利2元（含税）。 转自：证券时报 ...

Group 1 - The core point of the article is that Weili Medical (603309.SH) announced a cash dividend distribution plan for the first three quarters of 2025, proposing a cash dividend of 2 yuan (including tax) for every 10 shares held [1] - As of November 25, 2025, the total share capital of the company is 292 million shares, which results in a total proposed cash dividend distribution of 58.3743 million yuan (including tax) [1] - The proposed cash dividend amount accounts for 30.46% of the net profit attributable to the shareholders of the listed company in the consolidated financial statements for the first three quarters of 2025 [1]

证券日报网讯维力医疗（603309）11月24日在互动平台回答投资者提问时表示，公司根据上市公司相关 法规在定期报告披露公司股东人数，截至2025年9月30日，公司股东人数为18，890人。 ...

| 股票简称 | 股票代码 | 限售股类型 | 解禁股数 | | --- | --- | --- | --- | | 湖北能源 | 000883 | 股权激励限售流通 | 31.47万 | | 亚钾国际 | 000893 | 股权激励限售流通 | 240万 | | 南方航空 | 600029 | 增发A股原股东配售上市 | 8.04亿 | | 宁波韵升 | 600366 | 增发A股法人配售上市 | 3599.9万 | | 华兰生物 | 002007 | 股权激励限售流通 | 132.43万 | | 久其软件 | 002279 | 股权激励限售流通 | 244.78万 | | 吉峰科技 | 300022 | 股权激励限售流通 | 25万 | | 海默科技 | 300084 | 股权激励限售流通 | 270.9万 | | 金禾实业 | 002597 | 股权激励限售流通 | 54.64万 | | 维力医疗 | 603309 | 股权激励限售流通 | 3.3万 | | 艾德生物 | 300685 | 股权激励限售流通 | 153.63万 | | 海晨股份 | 300873 | 增发A股原股东配售上市 | 1726 ...

Core Viewpoint - The impact of the sixth round of national medical supplies procurement on the company is currently uncertain, as the official procurement plan has not yet been released [1] Group 1: Company Response - The company has established a dedicated department for procurement affairs management to study procurement policies and actively participate in each round of procurement [1] - The company aims to enhance the market coverage and share of its urology products in China through potential successful bids in this procurement round [1] - The company plans to implement cost reduction and efficiency improvement measures through production automation upgrades and technological advancements to enhance product profitability [1]

Core Insights - The report from Zhongyou Securities indicates that Weili Medical achieved a net profit attributable to shareholders of 192 million yuan in the first three quarters of 2025, representing a year-on-year growth of 14.94% [1] - In Q3, the net profit attributable to shareholders was 71 million yuan, reflecting a year-on-year increase of 16.31% [1] - The company's factory in Indonesia is nearing completion, with high-margin products increasingly contributing to revenue [1] Financial Performance - Net profit for the first three quarters of 2025 reached 192 million yuan, up 14.94% year-on-year [1] - Q3 net profit was 71 million yuan, marking a 16.31% year-on-year growth [1] Business Development - The Indonesian factory is currently in the construction and product certification phase, with expected shipments starting in the first quarter of 2026 [1] - The company is optimizing its overseas business product structure, with a continuous increase in the proportion of high-margin products [1] Future Outlook - The ongoing launch of new products is anticipated to further optimize the company's product and business structure [1] - The proportion of high-margin products is expected to continue rising, contributing to improved overall gross margins in overseas operations [1]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 20% relative to the benchmark index within the next six months [2][13]. Core Insights - The company achieved a revenue of 1.11 billion yuan in the first three quarters of 2025, representing a year-on-year growth of 12.33%. The net profit attributable to the parent company was 192 million yuan, up 14.94% year-on-year [4]. - The company is set to begin shipments from its Indonesian factory by the end of Q1 2026, which is expected to significantly boost export orders, particularly for high-margin products [5]. - The proportion of high-margin products in the company's revenue has exceeded 20% and is expected to continue increasing due to enhanced overseas sales efforts and the introduction of new products [5]. Financial Performance - For 2025, the company forecasts revenues of 1.72 billion yuan, 2.02 billion yuan in 2026, and 2.34 billion yuan in 2027, with year-on-year growth rates of 14.09%, 17.36%, and 15.54% respectively [6]. - The net profit attributable to the parent company is projected to be 259 million yuan in 2025, 315 million yuan in 2026, and 374 million yuan in 2027, with corresponding growth rates of 18.25%, 21.38%, and 18.85% [6]. - The company's price-to-earnings (P/E) ratios for 2025, 2026, and 2027 are estimated to be 15.87, 13.08, and 11.00 respectively, indicating a favorable valuation trend [6]. Business Strategy - The company has intensified its overseas expansion efforts, particularly in the urology product segment, which has shown significant growth in export revenues over the past two years [5]. - The Indonesian factory's initial capacity will primarily serve major clients in the U.S., focusing on the production of urinary catheters and suction connection tubes, with plans to expand into anesthesia products based on market demand [5].